GSK Oncology Portfolio Seems Underrated

Dow Jones07-17 21:51

1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.K. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. "The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade," the analysts say. "They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down." Shares fall 1.7%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

July 17, 2026 09:51 ET (13:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652666286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 21:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652666286","market":"fut","top_or_hot":-1,"title":"GSK Oncology Portfolio Seems Underrated","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. \"The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade,\" the analysts say. \"They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down.\" Shares fall 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 09:51 ET (13:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Oncology Portfolio Seems Underrated</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Oncology Portfolio Seems Underrated\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-17 21:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. \"The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade,\" the analysts say. \"They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down.\" Shares fall 1.7%. (adria.calatayud@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2026 09:51 ET (13:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2652666286","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2652666286","pubTimestamp":1784296260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.K. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. \"The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade,\" the analysts say. \"They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down.\" Shares fall 1.7%.  Dow Jones NewswiresJuly 17, 2026 09:51 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4007":"制药","GSKH":"GSK plc ADRhedged","LU1829250122.USD":"高盛欧洲核心股票组合Acc","GSK":"葛兰素史克"},"translate_title":"葛兰素史克肿瘤产品组合似乎被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"GSKH":0.6,"GSK":1.5},"content_text":"1351 GMT - GSK's oncology business has stronger assets than it is credited for and they could make a difference next decade, analysts at Jefferies say in a research note. The U.K. drugmaker has made a number of deals that add revenue potential without putting too much pressure on profitability and it still has room for more over the next few years, according to Jefferies. \"The acquisitions of IDRx as well as Nuvalent have added assets to the oncology portfolio that have one thing in common--long duration of therapy plus an ability to move up the treatment cascade,\" the analysts say. \"They are highly profitable assets that should start to contribute to the top-line as the HIV business starts to slow down.\" Shares fall 1.7%. (adria.calatayud@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2026 09:51 ET (13:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652666286","isCrawlerRequest":true}